Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03858712 · ClinicalTrials.gov registry record · NA
EHR-embedded OCDT in Breast or GI Cancer
A NA study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 100
- Enrollment target
NCT03858712 is a NA study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 100 participants.
The verdict
NCT03858712, a NA study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
Study Summary
This is research study is for participants with advanced breast or gastrointestinal cancer who have been taking oral chemotherapy medication (Oral Cancer Directed Therapy). This study is to help researchers better understand gaps in assessing oral chemotherapy patient toxicity at home, adherence to treatment and integrate toxicity/adherence reporting.
Interventions
- OTHER Active Care Team Alert
- OTHER Passive Care Team Alert
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2019-03-13 |
| Est. Completion | 2021-11-23 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03858712
The ClinicalTrials.gov registry entry for NCT03858712 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Active Care Team Alert is the first listed.
NCT03858712 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03858712 about?
NCT03858712 is a clinical study titled "EHR-embedded OCDT in Breast or GI Cancer". This is research study is for participants with advanced breast or gastrointestinal cancer who have been taking oral chemotherapy medication (Oral Cancer Directed Therapy). This study is to help researchers better understand gaps in assessing oral chemotherapy patient toxicity at home, adherence to ...
What is the current status of trial NCT03858712?
This trial is currently completed. It is a NA study. The enrollment target is 100 participants. The study started on 2019-03-13. Estimated completion is 2021-11-23.
What interventions are being tested in trial NCT03858712?
The interventions under investigation include: Active Care Team Alert (OTHER), Passive Care Team Alert (OTHER).
Who is sponsoring clinical trial NCT03858712?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.